Thrombocytopenia

Hematology
10
Pipeline Programs
6
Companies
11
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
4
0
2
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Amgen
NPLATEApproved
romiplostim
Amgen
Thrombopoietin Receptor Agonist [EPC]subcutaneous2008

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
3 programs
1
1
1
romiplostimPhase 41 trial
RomiplostimPhase 31 trial
RomiplostimPhase 21 trial
Active Trials
NCT00303472Completed72Est. May 2008
NCT00116688Completed313Est. Jan 2010
NCT00907478Completed169Est. Jan 2014
Hamilton medical
Hamilton medicalSwitzerland - Bonaduz
1 program
1
low dose of 2.25 x 10^11 platelets/transfusionPhase 31 trial
Active Trials
NCT00420914Terminated
Cellphire Therapeutics
2 programs
1
1
ThrombosomesPhase 21 trial
ThrombosomesPhase 11 trial
Active Trials
NCT03394755CompletedEst. Sep 2019
NCT04631211TerminatedEst. Jan 2022
E
EisaiChina - Liaoning
2 programs
1
1
AvatrombopagPhase 21 trial
avatrombopagPhase 11 trial
Active Trials
NCT02039076Completed48Est. Sep 2014
NCT01355289Completed65Est. May 2014
UP
UCB PharmaBelgium - Brussels
1 program
1
UCB7665Phase 21 trial
Active Trials
NCT02718716Completed66Est. Feb 2019
CT
2 programs
Group 1: single-dose of test formulation+single-dose of reference formulationN/A1 trial
Group 1: single-dose of test formulation+single-dose of reference formulationN/A1 trial
Active Trials
NCT06768632CompletedEst. Dec 2023
NCT06768619CompletedEst. Apr 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Amgenromiplostim
AmgenRomiplostim
Hamilton medicallow dose of 2.25 x 10^11 platelets/transfusion
Cellphire TherapeuticsThrombosomes
UCB PharmaUCB7665
EisaiAvatrombopag
AmgenRomiplostim
Cellphire TherapeuticsThrombosomes
Eisaiavatrombopag
Chia Tai TianQing Pharmaceutical GroupGroup 1: single-dose of test formulation+single-dose of reference formulation
Chia Tai TianQing Pharmaceutical GroupGroup 1: single-dose of test formulation+single-dose of reference formulation

Clinical Trials (11)

Total enrollment: 733 patients across 11 trials

NCT00907478Amgenromiplostim

Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)

Start: Aug 2009Est. completion: Jan 2014169 patients
Phase 4Completed
NCT00116688AmgenRomiplostim

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Start: Aug 2004Est. completion: Jan 2010313 patients
Phase 3Completed
NCT00420914Hamilton medicallow dose of 2.25 x 10^11 platelets/transfusion

Strategies for Transfusion of Platelets (SToP)

Start: Oct 2003
Phase 3Terminated
NCT04631211Cellphire TherapeuticsThrombosomes

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Start: Mar 2021Est. completion: Jan 2022
Phase 2Terminated
NCT02718716UCB PharmaUCB7665

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Start: Mar 2016Est. completion: Feb 201966 patients
Phase 2Completed
NCT01355289EisaiAvatrombopag

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Start: Nov 2011Est. completion: May 201465 patients
Phase 2Completed
NCT00303472AmgenRomiplostim

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Start: Feb 2006Est. completion: May 200872 patients
Phase 2Completed
NCT03394755Cellphire TherapeuticsThrombosomes

Thrombosomes® in Bleeding Thrombocytopenic Patients

Start: Mar 2018Est. completion: Sep 2019
Phase 1Completed
NCT02039076Eisaiavatrombopag

A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

Start: Dec 2013Est. completion: Sep 201448 patients
Phase 1Completed
NCT06768619Chia Tai TianQing Pharmaceutical GroupGroup 1: single-dose of test formulation+single-dose of reference formulation

Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State

Start: Mar 2023Est. completion: Apr 2023
N/ACompleted
NCT06768632Chia Tai TianQing Pharmaceutical GroupGroup 1: single-dose of test formulation+single-dose of reference formulation

Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State

Start: Jan 2020Est. completion: Dec 2023
N/ACompleted

Related Jobs in Hematology

Délégué Médical LLC/Myélome (H/F) - secteurToulouse

Johnson & Johnson
Issy-les-Moulineaux, France
Yesterday

MSL Hematología L - Sur

Johnson & Johnson
Sevilla, Spain
Yesterday

Senior Manager – Strategy & Business Transformation

Johnson & Johnson
Mumbai, India
Yesterday

Sr. Director Marketing

Genetix Biotherapeutics
Somerville, Massachusetts, United States
4d ago
From $270K/yr

Key Account Specialist Hematology

Johnson & Johnson
Beirut, Lebanon
4d ago

Hematology Field Medical Director, non-MD

Pfizer
Remote
4d ago
$177K - $294K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space

Related Indications

Anemia(92)Myelofibrosis(21)Polycythemia Vera(16)Primary Immune Thrombocytopenia(15)Primary Myelofibrosis(14)Immune Thrombocytopenia(12)Beta-Thalassemia(10)Aplastic Anemia(7)Anemia of Chronic Kidney Disease(7)Iron Deficiency Anemia(6)